Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

477

Participants

Timeline

Start Date

March 29, 2017

Primary Completion Date

June 1, 2018

Study Completion Date

July 31, 2018

Conditions
Respiratory Distress Syndrome
Interventions
DRUG

Aerosolized Calfactant

Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.

DEVICE

Solarys

Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.

Trial Locations (22)

14214

Sisters of Charity Hospital, Buffalo

22903

University of Virgina Medical Center, Charlottesville

27835

Pitt County Memorial Hospital, Greenville

29425

The Medical University of South Carolina, Charleston

31904

Columbus Regional Hospital, Columbus

32803

Adventist Healthcare System, Florida Hospital, Orlando

33176

Baptist Hospital of Miami, Miami

33606

University of South Florida, Tampa general, Tampa

33701

Johns Hopkins All Children's Hospital, St. Petersburg

36604

USA Children's & Women's Hospital, Mobile

37232

Vanderbilt university Medical Center, Nashville

38301

Jackson-Madison County General Hospital, Jackson

39216

University of Mississippi Medical Center, Jackson

40506

Kentucky Children's Hospital, University of Kentucky Medical Center, Lexington

55102

Children's Hospital Minnesota, Saint Paul

55404

Children's Hospital and Clinics, Minneapolis

61637

OSF Saint Francis Medical Center, Peoria

78258

North central Baptist Hospital, San Antonio

84057

Timpanogos Regional Medical Center, Orem

84604

Utah Valley Hospital, Provo

85006

Banner - University Medical Center Phoenix, Phoenix

92123

Sharp Mary Birch Hospital for Women & Newborns, San Diego

All Listed Sponsors
lead

ONY

INDUSTRY

NCT03058666 - Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients | Biotech Hunter | Biotech Hunter